Loading...
Experience With Afatinib in Patients With Non-Small Cell Lung Cancer Progressing After Clinical Benefit From Gefitinib and Erlotinib
BACKGROUND. Afatinib, an irreversible ErbB family blocker, demonstrated superiority to chemotherapy as first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Afatinib is also active in patients progressing on EGFR tyrosine kinase inhibitors (EGFR-TKIs). We report the...
Saved in:
Main Authors: | , , , , , , , , |
---|---|
Format: | Artigo |
Language: | Inglês |
Published: |
AlphaMed Press
2014
|
Subjects: | |
Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4200993/ https://ncbi.nlm.nih.gov/pubmed/25232040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0103 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|